{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:31:08Z","timestamp":1790087468510,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005595","name":"University of California","doi-asserted-by":"publisher","award":["PIK3CA"],"award-info":[{"award-number":["PIK3CA"]}],"id":[{"id":"10.13039\/100005595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005595","name":"University of California","doi-asserted-by":"publisher","award":["13,16"],"award-info":[{"award-number":["13,16"]}],"id":[{"id":"10.13039\/100005595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005595","name":"University of California","doi-asserted-by":"publisher","award":["PIK3C2G"],"award-info":[{"award-number":["PIK3C2G"]}],"id":[{"id":"10.13039\/100005595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.humpath.2024.04.012","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T06:39:34Z","timestamp":1714113574000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Plasmacytoid urothelial carcinoma of the urinary bladder\u2013A clinicopathological and molecular analysis of 52 cases"],"prefix":"10.1016","volume":"148","author":[{"given":"Lan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinchita","family":"Roy-Chowdhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alhalabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Siefker-Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna E.","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Czerniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2182-3287","authenticated-orcid":false,"given":"Charles C.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2024.04.012_bib1","article-title":"Urinary and male genital tumours. Lyon (France)","year":"2022","journal-title":"International Agency for Research on Cancer"},{"key":"10.1016\/j.humpath.2024.04.012_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/his.13752","article-title":"Variants and new entities of bladder cancer","volume":"74","author":"Lopez-Beltran","year":"2019","journal-title":"Histopathology"},{"issue":"Suppl 2","key":"10.1016\/j.humpath.2024.04.012_bib3","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1038\/modpathol.2009.26","article-title":"Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications","volume":"22","author":"Amin","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2024.04.012_bib4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"European Urology Focus"},{"key":"10.1016\/j.humpath.2024.04.012_bib5","first-page":"277","article-title":"Plasmacytoid transitional cell carcinoma. Report of a case with initial presentation mimicking multiple myeloma","volume":"35","author":"Sahin","year":"1991","journal-title":"Acta Cytol"},{"key":"10.1016\/j.humpath.2024.04.012_bib6","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.urology.2013.12.035","article-title":"Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes","volume":"83","author":"Kaimakliotis","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.humpath.2024.04.012_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.humpath.2019.04.012","article-title":"Plasmacytoid\/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients","volume":"90","author":"Perrino","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2024.04.012_bib8","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/ajcp\/aqx029","article-title":"Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 49 cases","volume":"147","author":"Fox","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2024.04.012_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.urology.2016.09.053","article-title":"Outcomes following radical cystectomy for plasmacytoid urothelial carcinoma: defining the need for improved local cancer control","volume":"102","author":"Cockerill","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.humpath.2024.04.012_bib10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.euf.2017.06.013","article-title":"The impact of plasmacytoid variant histology on the survival of patients with urothelial carcinoma of bladder after radical cystectomy","volume":"5","author":"Li","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.humpath.2024.04.012_bib11","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.juro.2012.11.084","article-title":"Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis","volume":"189","author":"Dayyani","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.humpath.2024.04.012_bib12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.path.2022.07.004","article-title":"Molecular taxonomy and immune checkpoint therapy in bladder cancer","volume":"15","author":"Guo","year":"2022","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.humpath.2024.04.012_bib13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2024.04.012_bib14","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1158\/0008-5472.CAN-09-4213","article-title":"Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome","volume":"70","author":"Lindgren","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2024.04.012_bib15","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sjodahl","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2024.04.012_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2024.04.012_bib17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2024.04.012_bib18","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2024.04.012_bib19","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng.3503","article-title":"Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer","volume":"48","author":"Al-Ahmadie","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2024.04.012_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.critrevonc.2017.11.010","article-title":"E-cadherin: its dysregulation in carcinogenesis and clinical implications","volume":"121","author":"Wong","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.humpath.2024.04.012_bib21","doi-asserted-by":"crossref","first-page":"10845","DOI":"10.18632\/oncotarget.14802","article-title":"Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2024.04.012_bib22","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2024.04.012_bib23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2024.04.012_bib24","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.humpath.2024.04.012_bib25","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1038\/s41598-020-66747-7","article-title":"Assessment of luminal and basal phenotypes in bladder cancer","volume":"10","author":"Guo","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.humpath.2024.04.012_bib26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"McConkey","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.humpath.2024.04.012_bib27","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2016.02.056","article-title":"Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer","volume":"70","author":"Guo","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.humpath.2024.04.012_bib28","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.celrep.2019.04.048","article-title":"Dysregulation of EMT drives the progression to clinically aggressive sarcomatoid bladder cancer","volume":"27","author":"Guo","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.humpath.2024.04.012_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101201","article-title":"Urothelial-to-Neural plasticity drives progression to small cell bladder cancer","volume":"23","author":"Yang","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.humpath.2024.04.012_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41585-023-00847-7","article-title":"Molecular profile of bladder cancer progression to clinically aggressive subtypes","author":"Guo","year":"2024","journal-title":"Nat Rev Urol"},{"issue":"12","key":"10.1016\/j.humpath.2024.04.012_bib31","first-page":"11","article-title":"Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC","volume":"40","author":"Kossa\u00ef","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.humpath.2024.04.012_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2018.10.033","article-title":"Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations","volume":"85","author":"Palsgrove","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2024.04.012_bib33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.humpath.2024.04.012_bib34","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.2353\/ajpath.2010.090872","article-title":"Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma","volume":"176","author":"Hansel","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.humpath.2024.04.012_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061555","article-title":"Emerging roles for mammalian target of rapamycin (mTOR) complexes in bladder cancer progression and therapy","volume":"14","author":"Huan","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.humpath.2024.04.012_bib36","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1002\/cncr.25502","article-title":"Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy","volume":"116","author":"Schultz","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2024.04.012_bib37","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.humpath.2012.07.009","article-title":"Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder","volume":"44","author":"Gonzalez-Roibon","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2024.04.012_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.01.005","article-title":"mTOR inhibitors in cancer therapy","volume":"319","author":"Zaytseva","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.humpath.2024.04.012_bib39","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int"},{"key":"10.1016\/j.humpath.2024.04.012_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043720","article-title":"HER2 expression in bladder cancer: a focused view on its diagnostic, prognostic, and predictive role","volume":"24","author":"Sanguedolce","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.humpath.2024.04.012_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/srep42713","article-title":"Her2 alterations in muscle-invasive bladder cancer: patient selection beyond protein expression for targeted therapy","volume":"7","author":"Kiss","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.humpath.2024.04.012_bib42","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.eururo.2015.01.014","article-title":"ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy","volume":"69","author":"Groenendijk","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.humpath.2024.04.012_bib43","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00428-015-1729-4","article-title":"Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer","volume":"466","author":"Tschui","year":"2015","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2024.04.012_bib44","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/modpathol.2011.69","article-title":"HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization","volume":"24","author":"Ching","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2024.04.012_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8463731","article-title":"HER2 protein overexpression and gene amplification in plasmacytoid urothelial carcinoma of the urinary bladder","volume":"2016","author":"Kim","year":"2016","journal-title":"Dis Markers"},{"key":"10.1016\/j.humpath.2024.04.012_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat Rev"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724000649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724000649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T17:42:22Z","timestamp":1715103742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817724000649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":46,"alternative-id":["S0046817724000649"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2024.04.012","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasmacytoid urothelial carcinoma of the urinary bladder\u2013A clinicopathological and molecular analysis of 52 cases","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2024.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}